Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555691 | 0.90 | NPSR1 (0.44) | LMNASMN1; SMN2CTSDMAPK1TP53 | |
| SCHEMBL3554476 | 0.90 | LMNA (0.45) | HTR2ALMNACCR5TP53 | |
| SCHEMBL3556717 | 0.89 | CCR5 (0.45) | POLBHTR2ACCR5TP53MAPT | |
| SCHEMBL3556349 | 0.88 | CCR5 (0.52) | POLBRXFP1HTR2ALMNASMN1; SMN2 | |
| SCHEMBL301764 | 0.86 | MEN1 (0.45) | POLBRXFP1HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3560963 | 0.84 | NAMPT (0.46) | POLBRXFP1HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3563793 | 0.83 | RXFP1 (0.48) | POLBRXFP1HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3558081 | 0.83 | HTR2A (0.49) | RXFP1HTR2ALMNACCR5MAPT | |
| SCHEMBL3555629 | 0.81 | RXFP1 (0.42) | POLBRXFP1HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3562435 | 0.81 | L3MBTL1 (0.53) | POLBRXFP1HTR2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | POLB 4709/4885RXFP1 232/4885HTR2A 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.